2,3-Didehydro-3-deoxy-4-ethynylthymidine (4-Ed4T) has been identified as a novel nucleoside analog with potent and selective anti-human immunodeficiency virus type 1 (HIV-1) activity and weak cytotoxicity in cell cultures. 4-Ed4T proved to be 5-to 10-fold more active than its structurally related compound, stavudine (d4T). However, the drug resistance profile of 4-Ed4T was different from those of d4T and other existing HIV-1 nucleoside reverse transcriptase inhibitors (NRTIs). Approximately 6-to 11-fold decreases in susceptibility to 4-Ed4T were observed for HIV-1 carrying NRTI-associated mutations (D67N, K70R, T215F, and K219Q) or the lamivudine (3TC)-resistant mutation M184V. In contrast, the susceptibility of the virus carrying the K65R mutation or the multidrug-resistant mutation with the Q151M complex (A62V, V75I, F77L, F116Y, and Q151M) was not altered. Furthermore, the activity of 4-Ed4T appeared to be enhanced in the presence of K103N, a major nonnucleoside reverse transcriptase inhibitor-resistant mutation. Although 4-Ed4T was 4.5-to 17.5-fold less active against multidrug-resistant clinical isolates than against a reference strain isolated from a treatment-naïve patient, it was still inhibitory to these isolates at low concentrations. Analysis of 4-Ed4T-resistant HIV-1 obtained through in vitro selection revealed that the virus was also resistant to 3TC and had two amino acid mutations (P119S and T165A) in addition to the M184V mutation. Since 4-Ed4T has increased anti-HIV-1 activity, decreased cytotoxicity, and a different resistance profile, it should be considered for further development as a new member of NRTIs.
Significant progress in the treatment of human immunodeficiency virus type 1 (HIV-1) infection has been achieved by the advent of highly active antiretroviral therapy (HAART), which targets different steps in the viral replication cycle with multiple inhibitors (40) . At present, one entry inhibitor, eight nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), three nonnucleoside reverse transcriptase inhibitors (NNRTIs), and eight protease inhibitors (PIs) are available for the treatment of HIV-1 infection. HAART with these inhibitors has brought about high-level suppression of viral load in patients. However, the emergence of drug-resistant HIV-1 mutants often results in the failure of therapy (18) . In case of treatment failure with existing antiretrovirals, there are few chemotherapeutic options because of cross-resistance among the inhibitors belonging to the same class. Therefore, it seems still mandatory to discover novel anti-HIV-1 agents with different resistance profiles.
Inhibition of viral entry is a promising approach, and the fusion inhibitor enfuvirtide (T-20) has shown efficacy in treatment-experienced patients (8, 12) . In addition, discovery of the chemokine receptors CCR5 and CXCR4 as HIV-1 coreceptors has led to another approach for controlling viral entry into the host cells (5, 34) . Several groups have reported structurally diverse small-molecule CCR5 antagonists, and some of them are now under clinical evaluation (4, 27, 36) . However, these CCR5 antagonists may not be used in the first-line antiretroviral therapy, since their resistance profiles as well as clinical efficacy have not fully been elucidated yet.
NRTIs, including zidovudine (AZT or ZDV), didanosine (ddI), lamivudine (3TC), and stavudine (d4T), are still the most important class of anti-HIV-1 agents. In fact, HAART is generally initiated with two NRTIs plus one NNRTI, such as nevirapine (NVP) or efavirenz (EFV), or two NRTIs plus one PI. Among the NRTIs, d4T proved to be a highly potent inhibitor of HIV-1 replication in vitro (2, 15, 25) . However, the use of d4T in vivo is rather limited by a long-term delayed toxicity, namely, peripheral sensory neuropathy caused by mitochondrial damage (7, 19, 29) . In contrast, the cytidine analog with the unnatural l-configuration, 3TC, and its 5-fluoro analog FTC (emtricitabine) have good anti-HIV-1 activity and favorable mitochondrial toxicity (6, 14, 24) . However, like NNRTIs, rapid emergence of highly resistant mutants is a serious drawback associated with the use of 3TC and FTC (22) .
Our continuous efforts to search for novel NRTIs with potent anti-HIV-1 activity, low toxicity, and a lack of cross-resistance to existing anti-HIV-1 agents have recently identified the 4Ј-substituted nucleoside analog 2Ј,3Ј-didehydro-3Ј-deoxy-4Ј-ethynylthymidine (4Ј-Ed4T). 4Ј-Ed4T is structurally related to d4T (Fig. 1) . It was recently found to be more active against HIV-1 replication and much less inhibitory to mitochondrial DNA synthesis in cell cultures than d4T (13) . Furthermore, 4Ј-Ed4T displayed synergistic anti-HIV-1 activity, when com-of infection (MOI) of 0.02 and were cultured in the presence of various concentrations of the test compounds. After a 4-day incubation at 37°C, the number of viable cells was monitored by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide method (33) . The cytotoxicity of the compounds was evaluated in parallel with their antiviral activity, based on the viability of mock-infected cells.
For the assay in PBMCs, PHA-stimulated PBMCs were inoculated with 1,000 to 1,400 50% cell culture infective doses of R5 HIV-1 (Ba-L) or X4 HIV-1 (III B ) or 1 to 10 ng of p24 of clinical isolates per 1 ϫ 10 6 cells and incubated for 4 h. The cells were washed to remove unadsorbed viral particles and seeded into a 96-well plate (1 ϫ 10 5 cells/well) with culture medium containing various concentrations of test compounds. On day 4 after infection, the cells were subcultured at 1:2 with culture medium containing the same concentration of the test compounds. On day 7, the culture supernatants were collected and determined for their p24 antigen levels by a p24 antigen enzyme-linked immunosorbent assay kit (ZeptoMetrix Corp., Buffalo, NY).
For the assay in MAGI-CCR5 cells, the cells were seeded in a 96-well plate at 1 ϫ 10 4 cells/well. The culture supernatants were removed on the next day, and fresh culture medium containing approximately 300 focus-forming units of the virus (A012B, A012D, or recombinant clones) and various concentrations of the test compounds were added to each well. On day 2 after viral infection, the culture supernatants were removed and fixing solution (1% formaldehyde and 0.2% glutaraldehyde in phosphate-buffered saline [PBS]) was added to each well. The cells were fixed at room temperature for 5 min and washed twice with PBS. X-Gal (5-bromo-4-chloro-3-indolyl-␤-D-galactopyranoside) (staining solution) (4 mM potassium ferrocyanide, 4 mM potassium ferricyanide, 2 mM magnesium chloride, and 0.4 mg of 5-bromo-4-chloro-3-indoyl-␤-D-galactosidase in PBS) was added to each well, and the cells were stained at 37°C for 45 min. The number of infected (blue) cells was counted microscopically.
Selection of drug-resistant HIV-1 in vitro. To obtain the virus resistant to 4Ј-Ed4T, long-term culture of virus-infected cells was conducted according to the previously described method with a slight modification (32) . Briefly, MT-4 cells were infected with HIV-1 (III B ) at an MOI of 0.02. After a 2-h incubation for viral adsorption, the cells were washed thoroughly with culture medium to remove unadsorbed viral particles. The cells (5 ϫ 10 5 cells) were incubated in a culture flask containing various concentrations of the test compounds. After a 4-day incubation at 37°C, the cells were subcultured with fresh culture medium containing appropriate concentrations of the compounds and further incubated. At the time of subcultivation, the cells were carefully checked microscopically. When the cells were completely destroyed by virus-induced cytopathogenicity, the culture supernatants were collected. The cells were subsequently infected with the supernatants and further incubated in the presence of escalating concentrations of the test compounds. At the end of long-term culture, the breakthrough virus was once propagated in MT-4 cells in the absence of compounds. The virus and infected cells were subjected to a drug susceptibility test and RT nucleotide sequence analysis, respectively.
RT nucleotide sequence analysis. Genomic DNA was extracted from the infected cells with a DNA extraction kit (Wako, Tokyo, Japan). The extracted DNA was amplified by PCR. The PCR consisted of 35 cycles with the primer pair SA009 (5Ј-TTTAAATTTTCCCATTAGCCCTAT-3Ј) and SA015 (5Ј-ACTCCA TGTACTGGTTCTTTTAGA-3Ј), which generated a fragment including codons 1 through 317 of HIV-1 RT (21). The amplifed products were isolated from 2% agarose gels and purified with a PCR DNA and Gel Band purification kit (Amersham Pharmacia Biotech, Piscataway, NJ). The purified DNA was sequenced directly with a cycle sequence kit (BigDye Terminator v1.1; Applied Biosystems Inc., Foster City, CA), using both forward and reverse primers on an automated DNA sequencer (model 310; Applied Biosystems Inc.).
RESULTS
Anti-HIV-1 activity of 4-Ed4T. When 4Ј-Ed4T, d4T, and 3TC were examined for their inhibitory effects on HIV-1 replication in MT-4 cells, 4Ј-Ed4T was found to be the most active among the three compounds ( Table 1 ). The 50% effective concentrations (EC 50 s) of 4Ј-Ed4T, d4T, and 3TC were 0.070, 0.31, and 0.60 M, respectively, indicating that 4Ј-Ed4T was approximately fourfold more potent than the parental compound d4T. This result correlated well with our previous result in MT-2 cells, although the EC 50 s of both compounds tended to be higher in MT-2 cells than those in MT-4 cells. 4Ј-Ed4T proved highly active against both X4 and R5 laboratoryadapted HIV-1 strains (III B and Ba-L, respectively) in PBMCs ( Table 1 ). The EC 50 s against the III B and Ba-L strains were 0.0019 and 0.0076 M, respectively. These values were 6-to 10-fold lower than those of d4T. On the other hand, 4Ј-Ed4T was less cytotoxic than d4T in mock-infected MT-4 cells and PBMCs. The 50% cytotoxic concentrations (CC 50 s) of 4Ј-Ed4T and d4T were Ͼ100 and 79 M, respectively, in MT-4 cells and 56 and 28 M, respectively, in PBMCs. These results suggest that 4Ј-Ed4T is a more potent and selective inhibitor of HIV-1 replication in vitro than d4T. Activity of 4-Ed4T against RT inhibitor-resistant mutants. 4Ј-Ed4T and other RT inhibitors were examined for their inhibitory effects on various RT inhibitor-resistant mutants in MAGI-CCR5 cells. Table 2 shows the EC 50 s of five NRTIs, including 4Ј-Ed4T, and one NNRTI against six RT inhibitorresistant mutants as well as two corresponding wild-type strains. Table 2 also displays the fold increase in EC 50 s against the mutants, based on the EC 50 values. The A012D contains four of the NRTI-associated mutations (NAMs), such as D67N, K70R, T215F, and K219Q, and was previously reported as an AZT-resistant strain (23) . In fact, A012D was highly resistant to AZT and approximately 210-fold less susceptible than its wild-type A012B. 4Ј-Ed4T was found to be 6.7-fold less active against A012D than against A012B. Interestingly, the anti-HIV-1 activity of 4Ј-Ed4T was not affected by the K65R mutation and the multidrug-resistant (MDR) mutation Q151M complex (A62V, V75I, F77L, F116Y, and Q151M). The K65R mutation is known to confer resistance to tenofovir (TFV) and some other NRTIs (28, 31, 39) , while the Q151M complex is able to confer resistance to most of the clinically licensed NRTIs (35) . In fact, a considerable decrease in anti-HIV-1 activity was observed for AZT, d4T, and ddI against the Q151M complex strain ( Table 2) .
Another interesting finding is that the anti-HIV-1 activity of 4Ј-Ed4T was weakened by the M184V mutation, which confers a high level of resistance to 3TC (Table 2 ). An approximately 11-fold decrease in anti-HIV-1 activity was observed for 4Ј-Ed4T against the M184V mutant of the HXB-2-based molecular clone, although the degree of reduced activity was not comparable to that of 3TC (Table 2) . Furthermore, the K103N mutation, which confers a high level of resistance to NNRTIs, appeared to increase the susceptibility to 4Ј-Ed4T and d4T. To confirm this observation, the NL4-3-based molecular clones carrying the mutation(s) of K103N alone, M184V alone, and both were examined for their susceptibility to 4Ј-Ed4T, d4T, 3TC, and NVP in MAGI-CCR5 cells. Again, moderate decrease and increase in the activity of 4Ј-Ed4T were observed against the M184V and K103N mutants, respectively (Table 3) . However, different from the observation with the HXB-2-based molecular clones, the anti-HIV-1 activity of d4T was unaffected irrespective of the absence or presence of the K103N mutation. Although the K103N and M184V mutations 
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seem to independently affect the activity of 3TC and NVP, the EC 50 of 4Ј-Ed4T against the double (K103N ϩ M184V) mutant resulted in being similar to that against the wild type (Table 3) .
Activity of 4-Ed4T against drug-resistant clinical isolates.
In the next experiment, 4Ј-Ed4T was examined for its inhibitory effect on the replication of four multidrug-resistant clinical isolates in PBMCs. The KK strain isolated from a treatmentnaïve patient was used as a reference strain. The NRTI-associated mutations of the clinical isolates used in this study are listed in Table 4 . In addition to these mutations, these strains showed considerable resistance to NNRTIs (NVP and EFV) and several PIs (Dr. Oka, personal communication). As shown in Table 4 , 4Ј-Ed4T proved highly active against the KK strain, which does not carry known NRTI-associated amino acid mutations (data not shown), with an EC 50 of 0.020 M. The anti-HIV-1 activity of 4Ј-Ed4T appeared to be somewhat reduced against the four clinical isolates compared to the KK strain. Its EC 50 s for these clinical isolates ranged from 0.089 to 0.35 M (Table 4) .
Susceptibility and amino acid mutations of 4-Ed4T-resistant virus. After a serial passages of the infected MT-4 cells in the presence of increasing concentrations of 4Ј-Ed4T or 3TC, breakthrough viruses were obtained in the presence of 20 M 3TC on day 29 and 2 M 4Ј-Ed4T on day 81 after virus infection (Fig. 2) . When the breakthrough viruses as well as the parental III B strain were examined for their susceptibility to 4Ј-Ed4T, d4T, and 3TC, the breakthrough viruses in the presence of either 3TC [III B (3TC 29D )] or 4Ј-Ed4T [III B (4Ј-Ed4T 26D ) and III B (4Ј-Ed4T 81D )] were completely resistant to 3TC (Table 5 ). 3TC could not inhibit the replication of these viruses at concentrations up to 100 M. In contrast, d4T was equally inhibitory to III B , III B (3TC 29D ), III B (4Ј-Ed4T 26D ), and III B (4Ј-Ed4T 81D ). 4Ј-Ed4T was found to be 8-, 2.9-, and 130-fold less active against III B (3TC 29D ), III B (4Ј-Ed4T 26D ), and III B (4Ј-Ed4T 81D ), respectively, compared with the wild type. Analysis for RT amino acid mutations revealed that III B (3TC 29D ) and III B (4Ј-Ed4T 26D ) had one amino acid mutation, M184V, while an additional two mutations, P119S and T165A, were identified in the RT of III B (4Ј-Ed4T 81D ). These results suggest that the M184V mutation confers some resistance to 4Ј-Ed4T, yet additional mutations are required for HIV-1 to obtain a high level of resistance to 4Ј-Ed4T.
DISCUSSION
The anti-HIV-1 activities of 4Ј-substituted nucleoside analogs have been synthesized and examined for their antiviral activities. Among the compounds, 4Ј-azidothymidine (4Ј-AZT) and 4Ј-methoxythymidine were reported to inhibit HIV-1 replication in vitro (26) . More recently, a series of 4Ј-ethynyl nucleoside analogs has been identified as highly potent and selective inhibitors of HIV-1 replication (20) . These analogs were not further investigated for their clinical potential as novel antiretroviral agents because of their toxicity in vivo. They had the 2Ј-deoxyribose configuration instead of 2Ј,3Ј-dideoxyribose configuration. It is possible that the compounds are recognized as a substrate by cellular DNA polymerases and incorporated into the host DNA due to the presence of a hydroxy group at the 3Ј position (10) . To circumvent the interaction with cellular DNA polymerases, 4Ј-substituted 2Ј,3Ј-dideoxynucleoside analogs have been designed and examined for their anti-HIV-1 activity. However, removal of the 3Ј-hydroxy group (2Ј,3Ј-dideoxy and 2Ј,3Ј-didehydro-2Ј,3Ј-dideoxy configurations) in 4Ј-substituted nucleosides resulted in complete loss of the antiviral activity (26) .
During our investigations on the reaction of organometallic reagents with 4Ј,5Ј-epoxy nucleosides, we have established the synthesis of 4Ј-substituted d4T derivatives and examined them for their anti-HIV-1 activity (16, 17) . To our surprise, 4Ј-Ed4T and 4Ј-cyano-d4T proved to be highly potent inhibitors of HIV-1 replication in cell cultures. 4Ј-Ed4T was more active against laboratory-adapted HIV-1 strains in T-cell lines and PBMCs and less cytotoxic to the host cells than d4T ( Table 1) . The ideal NRTI must be recognized by host cellular kinases and converted to its 5Ј-triphosphate form with high efficiency. In addition, the nucleoside 5Ј-triphosphate must interact preferentially with HIV-1 RT but not with cellular DNA polymerases. Toxicity of NRTIs may be related to inhibition of mitochondrial DNA polymerase ␥ (1). In fact, our previous study clearly showed that the efficiency of human thymidine kinase in the phosphorylation of 4Ј-Ed4T was fourfold better than that of d4T (13) . The study also demonstrated that 4Ј-Ed4T did not affect the mitochondrial DNA synthesis in the human T-cell line CEM at concentrations up to 100 M, whereas d4T and zalcitabine reduced its mitochondrial DNA content by 50% at concentrations of 9.3 and 0.15 M, respectively. Although the direct inhibition of human DNA polymerase ␥ by the 5Ј-triphosphate form of 4Ј-Ed4T (4Ј-Ed4T-TP) remains to be examined, 4Ј-Ed4T-TP may not be a good substrate of this enzyme. Furthermore, it is hardly conceivable that 4Ј-Ed4T is converted to d4T during its metabolic process and that one of its metabolites acts as an NNRTI, since this compound was also active against simian immunodeficiency virus replication (data not shown).
In this study, we have examined the anti-HIV-1 activity of 4Ј-Ed4T against a variety of NRTI-resistant strains, including clinical isolates, to elucidate the resistance profiles of this compound and obtained several interesting findings (Tables 2 and  3) . First, a moderate decrease in susceptibility to 4Ј-Ed4T was observed for the mutant carrying NAMs. Second, a moderate decrease in susceptibility was also observed for the 3TC-resistant (M184V) mutant. Third, the susceptibility of the mutants carrying K65R or the Q151M complex was not altered. Fourth, the activity of 4Ј-Ed4T appeared to be enhanced in the presence of the NNRTI resistance mutation K103N. These results suggest that 4Ј-Ed4T has different drug resistance profiles. The molecular mechanism of the enhanced activity of 4Ј-Ed4T against the K103N mutant is unclear and an important subject to be determined. From a practical point of view, this nature of 4Ј-Ed4T seems beneficial, since many HIV-1-infected individuals are currently treated with a 3TC-and NNRTI-containing regimen. Thus, a certain proportion of such individuals may carry the double (K103N ϩ M184V) mutants after long-term treatment (11) .
To predict the emergence of drug-resistant mutants in vivo, a long-term culture experiment with HIV-1-infected cells in the presence of 4Ј-Ed4T was conducted. Analysis for the amino acid sequences in the RT of breakthrough viruses revealed that the M184V mutation conferred a modest degree of resistance to 4Ј-Ed4T (Table 5 ). However, unlike 3TC, an additional mutation (either P119S or T165A) or even both mutations may be required for a high level of resistance to 4Ј-Ed4T, since the intermediate breakthrough virus [III B (4Ј-Ed4T 26D )] obtained on day 26 in the presence of 4Ј-Ed4T was found to have only the M184V mutation and retain considerable susceptibility to 4Ј-Ed4T (Fig. 2 and Table 2 ). Tanaka et al. reported that the P119S mutation conferred resistance to 2Ј-␤-fluoro-2Ј,3Ј-deoxyadenosine (F-ddA) (38) . Although an additional two mutations (V179D and L214F) were frequently associated with this mutation, the P119S mutation proved to be directly responsible for the reduced susceptibility of HIV-1 to F-ddA. They assumed that the additional mutations compensated for the reduction in viral replication capacity (fitness) brought about by the P119S mutation. It could be possible that one of P119S and T165A mutations could enhance the resistance of M184V mutants to 4Ј-Ed4T and that the other could improve viral fitness. Further experiments, such as susceptibility tests of infectious molecular clones with either the P119S or T165A mutation, are required to clarify the role of each mutation.
In conclusion, 4Ј-Ed4T is a novel nucleoside analog with a unique chemical structure. The compound is a potent and selective inhibitor of HIV-1 replication and is less cytotoxic to the host cells than d4T in vitro. 4Ј-Ed4T also shows a unique drug resistance profile that clearly differs from that of known NRTIs. Since 4Ј-Ed4T has favorable oral bioavailability in mice (unpublished data), toxicity tests in animals have been initiated for further evaluation of its potential as an anti-HIV-1 agent.
